Eskiizmir, GKoçal, GÇUysal, TEllidokuz, HBaspinar, Y2024-07-182024-07-181749-44781749-4486http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/5663Objectives To determine the serum hypoxia-inducible factor-1, -2 and -3 (HIF-1, -2 and -3) levels in patients with laryngeal neoplasm, and to investigate their role in differential diagnosis, prediction of tumour characteristic and extension, and prognosis and survival. Study Design Prospective, cohort study at a tertiary referral centre. Settings The study was conducted in a tertiary medical centre. Participants Patients with benign, premalignant and malignant laryngeal neoplasms were included. Sixty-four patients with a laryngeal neoplasm were enrolled. Main Outcome Measures Serum HIF-1, -2 and -3 levels were measured from blood samples that were drawn before treatment, using ELISA. Results A statistically significant difference between benign (HIF-1, -2, -3:4046,1 pg/mL; 2581,5 pg/mL; 1321,0 pg/mL), premalignant (HIF-1, -2, -3:3630,3 pg/mL; 3229,7 pg/mL; 2549,8 pg/mL) and malignant (HIF-1, -2, -3:3576,7 pg/mL; 2595,8 pg/mL; 1106,3 pg/mL) laryngeal neoplasms was not detected when serum HIF-1, -2 and -3 levels were compared. However, high serum HIF-2 level adversely affected survival and locoregional control and had more than 7-fold increase in hazard ratio. Moreover, serum HIF-2 was an independent prognostic factor for 2-year overall, disease-free, distant metastasis-free survival and locoregional control. Conclusion This is the first clinical study in which the diagnostic, predictive and prognostic roles of hypoxia-related biomolecules were examined in laryngeal neoplasms. Hypoxia-inducible factor-2 is a prognostic factor in larynx cancer irrespective of treatment modality.EnglishSQUAMOUS-CELL CARCINOMATUMOR MICROENVIRONMENTCA-IXCLINICAL-RELEVANCEPREDICTIVE-VALUEGROWTH-FACTORRISK-FACTORSHEADHIF-2-ALPHAANEMIAArticle